For the best experience on the Abcam website please upgrade to a modern browser such as
Rabbit polyclonal to Hexokinase Type III
Predicted to work with:
Recombinant fragment, corresponding to a region within amino acids 587-786 of Human Hexokinase Type III (UniProt P52790).
Hela whole cell lysate; A549 and HCT116 cell lysates; Hela cells
Shipped at 4°C. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Preservative: 0.01% Thimerosal (merthiolate) Constituents: 78% PBS, 20% Glycerol, 1% BSA
Concentration information loading...
Immunogen affinity purified
Abpromise guarantee covers the use of
in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/500 - 1/3000. Predicted molecular weight: 99 kDa.
1/100 - 1/500.
Carbohydrate metabolism; hexose metabolism.
Belongs to the hexokinase family.
The N- and C-terminal halves of this hexokinase show extensive sequence similarity to each other. The catalytic activity is associated with the C-terminus while regulatory function is associated with the N-terminus.
Information by UniProt
ATP:D hexose 6 phosphotransferase antibody
Hexokinase type III antibody
Western blot - Anti-Hexokinase Type III antibody (ab126217)
Anti-Hexokinase Type III antibody (ab126217) at 1/1000 dilution + Hela whole cell lysate at 30 µg
Predicted band size: 99 kDa 7.5% SDS PAGE
Immunocytochemistry/ Immunofluorescence - Anti-Hexokinase Type III antibody (ab126217)
ab126217, at 1/500 dilution, staining Hexokinase Type III in methanol fixed Hela cells by Immunofluorescence.
The image in the lower panel was costained with Hoechst 33342.
This product has been referenced in:
et al. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance. JCI Insight 2:e88815 (2017).
Read more (PubMed: 28138554) »
et al. Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells. PLoS One 9:e104104 (2014).
Read more (PubMed: 25090630) »
See all 2 Publications
for this product
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"